Efficacy and Safety of KW21052 Compared to Lyrica in the Diabetic Patients With Neuropathic Pain
Status:
Unknown status
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Diabetic neuropathy is known to be the most common complication of diabetes, although the
estimated prevalence is highly variable, ranging from 1.6 to 90%. Also, chronic pain is
accompanied with sleep disorders, depression, and anxiety, thereby impairing quality of life
and increasing societal costs. Pregabalin is one of proven and marketed oral medicine to
manage the chronic neuropathic pain in diabetic patients. This study is designed as a
randomized controlled trial to demonstrate that the efficacy of KW21052 in pain reduction
measured by the weekly mean pain score on the numerical pain rating scale (NRS) at the 8th
week of intervention is inferior to that of Lyrica.